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Nesfatin-1, a satiety-inducing peptide identified in hypothalamic regions that regulate energy bal-
ance, is an integral regulator of energy homeostasis and a putative glucose-dependent insulin coad-
juvant. We investigated its production by human cardiomyocytes and its effects on glucose uptake, in
the main cardiac glucose transporter GLUT-4 and in intracellular signaling. Quantitative RT-PCR, West-
ern blots, confocal immunofluorescence microscopy, and ELISA of human and murine cardiomyocytes
and/or cardiac tissue showed that cardiomyocytes can synthesize and secrete nesfatin-1. Confocal
microscopy of cultured cardiomyocytes after GLUT-4 labeling showed that nesfatin-1 mobilizes this
glucose transporter to cell peripherals. The rate of 2-deoxy-D-[3H]glucose incorporation demonstrated
that nesfatin-1 induces glucose uptake by HL-1 cells and cultured cardiomyocytes. Nesfatin-1 induced
dose- and time-dependent increases in the phosphorylation of ERK1/2, AKT, and AS160. In murine and
human cardiac tissue, nesfatin-1 levels varied with diet and coronary health. In conclusion, human and
murine cardiomyocytes can synthesize and secrete nesfatin-1, which is able to induce glucose uptake
and the mobilization of the glucose transporter GLUT-4 in these cells. Nesfatin-1 cardiac levels are
regulated by diet and coronary health. (Endocrinology 154: 4757–4767, 2013)
Nesfatin-1 is an 82–amino acid peptide derived fromnucleobindin 2 (NUCB2) through processing by pro-
hormone convertases, the enzymes that process proinsulin
(1). First found in hypothalamic regions that regulate en-
ergy balance (1), it appears to act there (2) as an integral
regulator of energy homeostasis, circadian feeding
rhythm, and related endocrine functions (3, 4). It also cir-
culates in the bloodstream, plasma levels depending on
nutritional state and other metabolic circumstances (5–9).
It reduces food and water intake and body weight gain in
rodents (10–15), increases spontaneous physical activity
and whole-body fat oxidation (13), and raises body tem-
perature (14). These multiple metabolic effects and the
reported association between plasma glucose and nesfa-
tin-1 levels in rats and patients with type 2 diabetes (5, 8,
16) suggest that it is a glucose-dependent coadjuvant of
insulin (13, 17–20), whereas its dependence on the met-
abolic state has suggested that plasma nesfatin-1 levels
may be regulated by sustained changes in adipose tissue
mass and/or inflammatory status (6, 21), two of the most
important determinants of metabolic syndrome.
That peripheral sources of nesfatin-1 exist is suggested
by its ability to cross the blood-brain barrier and by re-
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ports of NUCB2 production, which is dependent on nu-
tritional status and/or sympathetic nerve activity, by pi-
tuitary gland, gastric endocrine cells, endocrine pancreas,
liver, subcutaneous and visceral adipose tissue, skeletal
muscle, and testis (6, 16, 22–24). However, the only re-
ported observations of endogenous fully processed nesfa-
tin-1 appear to be those of Oh-I et al (1) in rat cerebro-
spinal fluid and Angelone et al (25) in rat cardiac extracts.
Like many other peptides that regulate and/or are reg-
ulated by feeding and metabolism, nesfatin-1 can influ-
ence cardiovascular function. In rat studies, it has induced
negative inotropism and modulated lusitropism in per-
fused hearts (25) and increased sympathetic activity, mean
arterial pressure, and heart rate (26–28). To the best of our
knowledge, fully processed nesfatin-1 peptide has been
detected in the human circulation using a sandwich-type
ELISA (7), but it has never been identified in other human
tissues. In this study, we investigated its presence in human
cardiac tissue and its influence on correlated signaling pro-
teins (ERK1/2, AKT, and AS160) and on GLUT-4 mobi-
lization, and the effects of diet and cardiovascular disease
on its levels in cardiomyocytes.
Materials and Methods
All reagents were from Sigma-Aldrich unless otherwise
stated.
Ethics
The study protocol was approved by the Galician Clinical
Research Ethics Committee (2007/304). All acquisitions of hu-
man tissues were performed with informed consents and in ac-
cordance with the Declaration of Helsinki 2008 (and, when per-
tinent, the European Convention of Human Rights and
Biomedicine [ETS 164] and the UK Human Tissue Act 2004)
after approval by local medical/health research ethics commit-
tees. All animals were maintained and euthanized following pro-
tocols approved by the Animal Care Committee of the University
of Santiago de Compostela in accordance with European Union
Directive 2010/63.
Human tissue samples
Right atrial appendages were obtained from 268 patients un-
dergoing valve surgery or coronary artery bypass grafting (pa-
tient characteristics in Table 1). Ventricular tissue samples from
patients undergoing cardiac transplants (29) were donated by the
La Fe University Hospital (Valencia, Spain). Samples of human
stomachs (mucosa) were obtained from the Department of Di-
gestive Pathology of the University Clinical Hospital (Santiago
de Compostela, Spain).
Animals
Three- to four-week-old male Sprague-Dawley rats were fed
for 18 weeks with the standard diet (3.85 kcal/g; 10% fat [5.6%
soybean oil and 4.4% lard], 20% protein, and 70% carbohy-
drate [35% sucrose, 31% cornstarch, and 4% maltodextrin];
Research Diets, Inc] or the high-fat diet (4.73 kcal/g; 45% fat
[5.6% soybean oil and 39.4% lard], 20% protein, and 35%
carbohydrate [17% sucrose, 8% cornstarch, and 10% malto-
dextrin]; Research Diets, Inc.) and euthanized by decapitation.
Hearts were collected and quickly frozen at 80°C. Neonatal (1-
to 3-day-old) Sprague-Dawley rats were killed by cervical dis-
location, and their hearts were used for establishment of primary
cardiomyocyte cultures (see below).
Cell cultures
Cardiomyocytes from human atrial appendages and neonatal
rat hearts and adult mouse atrial HL-1 cardiomyocytes (a gift of
Dr. W. C. Claycomb of Louisiana State University Medical Cen-
ter, New Orleans, Louisiana) were all cultured as described pre-
viously (30). Adult human ventricular cardiomyocytes (Promo-
Cell GmbH) were cultured according to the supplier’s
instructions.
Quantitative PCR (qPCR)
Real-time RT-qPCR for NUCB2 was performed on RNA ex-
tracted with the RNeasy Total RNA Extraction Kit (QIAGEN)
using Master Mix and specific primers provided by SABio-
science (rat NUCB2, 145 bp, catalog no. PPR49435A, refer-
ence position 1245, GenBank NM_021663.2; rat GAPDH,
172 bp, catalog no. PPR06557A, reference position 363, Gen-
Table 1. Demographic and Clinical Characteristics of






Age, mean, y 69.07 69.77
BMI, mean, kg/m2 28.41 29.1
Normal weight (18.5–24.9 kg/m2),
n (%)
29 (16.3) 17 (18.8)
Overweight (25–29.9 kg/m2), n (%) 95 (53.3) 34 (37.7)
Obesity (30 kg/m2), n (%) 49 (27.5) 37 (41.1)
HTA, n (%) 129 (72.4) 67 (74.4)
T2DM, n (%) 51 (28.6) 22 (24.4)
HLP, n (%) 93 (52.2) 52 (57.7)
Laboratory findings
Triglycerides, mean, mg/dL 109.6 124.76
Cholesterol, mean, mg/dL 167.93 189.75
Glucose, mean, mg/dL 114.85 114.73
Drugs
Antiplatelets, n (%) 64 (35.9) 29 (32.2)
Anticoagulants, n (%) 35 (19.6) 20 (22.2)
ACE inhibitors, n (%) 53 (29.7) 22 (24.4)
ARBs, n (%) 37 (20.7) 20 (22.2)
-Blockers, n (%) 54 (30.3) 28 (31.1)
CCBs, n (%) 39 (21.9) 11 (12.2)
Diuretics, n (%) 95 (53.3) 41 (45.5)
OADs, n (%) 35 (19.6) 14 (15.5)
Insulin, n (%) 13 (7.3) 7 (7.7)
Cardiovascular pathologies
Coronary injury, n (%) 96 27
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin
II receptor blocker; BMI, body mass index; CCB, calcium channel
blocker; HLP, hyperlipidemia; HTA, arterial hypertension; OAD, oral
antidiabetic drug; T2DM, type 2 diabetes mellitus.
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Bank NM_017008.3; human NUCB2, 126 bp, catalog no.
PPH19934A, reference position 894, GenBank NM_005013.2;
human GAPDH, 175 bp, catalog no. PPH00150E, reference po-
sition 1287, GenBank NM_002046.3; mouse NUCB2, 95 bp,
catalog no. PPM25549A, reference position 1314, GenBank
NM 016773.3; and mouse GADPH, 140 bp, catalog no.
PPM02946E, reference position 309, GenBank NM 008084.2).
We also performed one-step real-time RT-PCR with a Brilliant
III SYBR Green QRT-PCR Master Mix Kit (Stratagene) for the
following specific primers: rat CD36, 92 bp, GCGACATGAT-
TAATGGCACA (forward) and CCTGCAAATGTCAGAG-
GAAA (reverse), GenBank NM 031561.2; and rat GADPH, 224
bp, GCTCATGACCACAGTCCATG (forward) and GGCAT-
GTCAGATCCACAAC (reverse), GenBank NM 017008.4. Re-
sults were analyzed using MxPro v4 software (Stratagene).
Western blotting
Cultured cardiomyocytes (50,000 cells/cm2) or heart tissues
were lysed and subjected to SDS-PAGE/Western blotting as pre-
viously described (31), using antibodies against nesfatin-1 resi-
dues 1 to 28 (Phoenix Pharmaceuticals), ERK1/2 and phospho-
ERK1/2 (Thermo Fisher Scientific), AKT and Ser-473–
phosphorylated AKT (Cell Signaling Technology), AS160 and
phospho-AS160 (Cell Signaling Technology), and -actin and
GAPDH (Thermo Fisher Scientific), all at 1:1000 dilutions ex-
cept for AS160 (1:500 dilution).
Immunocytochemistry
With use of an Autostainer Link 48 (Dako), primary cultures
of human and neonatal rat cardiomyocytes were stained with
FLEX mouse anti-desmin antibodies (clone D33; Dako) and rab-
bit anti-nesfatin-1 antibodies (Phoenix Pharmaceuticals), both at
1:200, followed by EnVision FLEX/HRP (Dako) for detection.
Normal goat serum or anti-nesfatin-1 antibody preadsorbed by
nesfatin-1 peptide (Phoenix Pharmaceuticals) was used as a neg-
ative control.
Immunocytofluorescence labeling and confocal
microscopy
Primary cultures of neonatal rat cardiomyocytes were de-
prived of serum for 12 hours before treatment with nesfatin-1
(0.01–1 M for 10 minutes or 1 M for 5–30 minutes) or 100
nM insulin. Cells (10,000 per A 12-mm circular coverslip), and
tissues were processed as described previously (31) using rabbit
antibodies: anti-GLUT-4 (Abcam) at 1:100 dilution, anti-nesfa-
tin-1 at 1:500 dilution or anti-prohormone convertase 1/3 (Ab-
cam) at 1:100 dilution. Quantitative confocal microscopy was
performed using a Leica DMIRE2 confocal microscope and soft-
ware to compare GLUT-4 concentrations in the cell peripherals
with those in the cytoplasm and perinuclear region, as other
authors have described previously for cardiomyocytes in culture
(31–34). A total of 216 cells were analyzed. For each coverslip,
a minimum of 6 distinct and randomly chosen visual fields were
photographed and analyzed as z-stacks using a Leica DMIRE2
confocal microscope and software. The mean intensity of Cy3
fluorescence was measured to indicate the relative expression
level of the GLUT-4 glucose transporter. To measure the inten-
sity of fluorescence in the cytoplasmic perinuclear region vs the
cell peripheral cytoplasmic membrane, regions of interest (ROIs)
of equal sizes were first set up manually, and then the cytoplasmic
perinuclear region and the cell peripheral cytoplasmic membrane
ROIs for each of several cells per field were chosen randomly and
measured automatically. Cells with any of the following char-
acteristics were excluded from analysis: atypically large or small
size; perceptibly in the G1 or later phase of the cell cycle; not in
contact with at least one neighbor; and outer cytoplasmic bor-
ders not clearly distinguishable from those of their neighbors.
Great care was taken to localize the ROIs well within the cell
cytoplasmic perinuclear and cell peripheral areas (as indicated by
the presence or absence of TO-PRO-3 fluorescence, respec-
tively). To maximize the number of cells measured and the ob-
jectivity with which ROI localization was carried out, the process
was performed twice, by 2 independent observers. Thus, more
than 70 ratios were obtained for each experimental variable.
Glucose uptake experiments
Serum-deprived HL-1 cells or neonatal rat cardiomyocytes
(104 per P24 well) were treated for 2.5 hours with nesfatin-1
(0.1–100 nM). Treatment for 1 hour with insulin (100 nM) was
used as a positive control. Cells were washed twice in glucose-
free HEPES-buffered saline solution at pH 7.4 (140 mM NaCl,
5 mM KCl, 2.5 mM MgSO4, 1 mM CaCl2, and 20 mM HEPES),
and glucose uptake was determined as described previously using
2-deoxy-D-[3H]glucose (PerkinElmer) (13). Nonspecific glucose
uptake was determined in the presence of 10 M cytochalasin B,
and the value obtained was subtracted from all other
measurements.
ELISAs
Plasma NUCB2/nesfatin-1 levels of male Sprague-Dawley
rats fed for 18 weeks with the standard or high-fat diet were
determined by ELISA (Phoenix Pharmaceuticals; minimum de-
tection limit, 0.8 ng/mL; range, 0.1–1000 ng/mL; linear range,
0.8–14.1 ng/mL; intra-assay error, 10%; interassay error,
15%). NUCB2/nesfatin-1 secretion by neonatal rat cardiomy-
ocytes was measured in the culture medium in 6-well plates in
which cells had been cultured for 3 days at a density of 4.5  105
cells/well.
Statistical analyses
All experimental data were obtained from at least 3 indepen-
dent experiments. The comparisons between groups of data were
performed with the appropriate test, depending on the normality
of the data. We used t tests with gaussian data, and Mann-Whit-
ney U, Kruskal-Wallis, and Wilcoxon signed rank tests with non-
gaussian data. All the correlation coefficients were measured as
Spearman r. All the analysis were done with SPSS 15.0 (IBM) or
Prism 5 (GraphPad Software).
Results
NUCB2 gene expression in human and murine
cardiomyocytes
qPCR showed NUCB2 mRNA in human cardiac tissue
and cardiomyocyte cultures (with the highest levels, sim-
ilar to those in stomach, in atrial tissue) (Figure 1A.1), in
rat cardiac tissues and cardiomyocyte cultures (with
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higher levels in atrial than in ventricular cells) (Figure
1B.1), and in mouse cardiac tissue and the adult mouse
atrial cell line HL-1 (Figure 1C.1). That reverse transcrip-
tionhadproceededproperlywas confirmed ineachcaseby
amplification of GAPDH, which was used to normalize all
the data.
Synthesis of nesfatin-1 by human and murine
cardiomyocytes
Western blots with anti-nesfatin-1 antibodies showed a
9.5-kDa band coinciding with the main band of commer-
cial nesfatin-1 peptide in human, rat, and mouse cardiac
tissue and/or cardiomyocytes (Figure 1, A.2, B.2, and C.2).
In rat (Figure 2, A.1 and Cd and e) and human (Figure 2,
Ba–c and Ca–c) cardiomyocytes from primary cultures,
the perinuclear cytoplasm was intensely immunoreactive
with anti-nesfatin-1 antibody (Figure 2A.1b). The possi-
bility that some reactive cells were fibroblasts was ruled
out by their immunoreactivity with antibodies against my-
osin heavy chain (data not shown) and/or desmin (Figure
2Cc) and by the use of a cytostatic agent in the culture
medium to prevent fibroblast proliferation. Similarly, the
cytoplasm of virtually all muscle fibers in sections of hu-
man atrial tissue was immunoreactive with anti-nesfatin-1
antibody (Figure 2Bd–f) and with anti-prohormone con-
vertase 1/3 antibody (Figure 2Bg–i). Control stains (nor-
mal goat serum or anti-nesfatin-1 antibody preadsorbed
bynesfatin-1peptide) stainedneither culturedcells (Figure
2, A.2 and Cb and e) nor cardiac tissues (data not shown).
Secretion of nesfatin-1 by primary cultures of rat
cardiomyocytes
Secretion of NUCB2/nesfatin-1 into the culture me-
dium was measured only in primary cultures of neonatal
rat cardiomyocytes due to the limited cardiomyocyte pop-
ulations afforded by human right atrial appendages in cul-
ture. In culture medium supporting approximately 4.5 
105 confluent starving cells, the ELISA-measured NUCB2/
nesfatin-1 concentration was 4.55  0.52 ng/mg of cel-
lular protein (n  21).
Effect of nesfatin-1 treatment on GLUT-4
mobilization in cardiomyocytes
Analysis of confocal images of cultured neonatal rat
cardiomyocytes with fluorescence-labeled GLUT-4
showed that 10 to 1000 nM nesfatin-1 caused significant
translocation of GLUT-4 to cell peripherals, decreasing its
amount in the cytoplasmic perinuclear area of the cardi-
omyocytes in a dose- and time-dependent fashion by a
factor similar to that caused by 100 nM insulin (Figure 3).

































































































Figure 1. Results of qPCR (A.1, B.1, and C.1) and Western blots (A.2, B.2, and C.2) comparing the levels of NUCB2 mRNA and nesfatin-1 peptide
(9.5-kDa band; the band at 50 kDa corresponds to full-length NUCB2 protein), respectively, in human (A), rat (B), and mouse (C) cardiac tissues
(ventricle and atrium for humans and rats and whole heart for mouse), cultured cardiomyocytes (adult human ventricular cardiomyocytes, neonatal
rat cardiomyocytes, and adult mouse HL-1 cells), and stomach (mucosa) tissue. Synthetic nesfatin-1 peptide was run for comparison in Western
blots. Bar graphs show means  SEM. a.u., arbitrary units.






















Figure 2. Nesfatin-1 in human and rat cardiomyocytes and myocardium (scale bar corresponds to 10 m in A.1b and 50 m elsewhere). A,
Confocal photomicrographs of primary neonatal rat cardiomyocyte cultures. A.1a, Perinuclear immunofluorescent nesfatin-1. A.1b, Detail of A.1a.
A.1c, TO-PRO-3 nuclear marker. A.1d, A.1a and A.1b merged. A.2a, Perinuclear immunofluorescent nesfatin-1. A.2b, No staining by anti-nesfatin-
1 antibody presaturated with nesfatin-1 (negative control). A.2c, A.2a merged with the corresponding TO-PRO-3 image. A.2d, A.2b merged with
the corresponding TO-PRO 3 image. B, Confocal photomicrographs of human atrial cardiomyocytes (a–c) or atrial tissue (d–i), showing
immunofluorescent perinuclear nesfatin-1 (a and d) or prohormone convertase 1/3 (g), the corresponding TO-PRO 3 images (b, e, and h), and the
merges of a and b, d and e, and g and h (c, f, and i). C, Immunostained nesfatin-1 in human atrial (a) and neonatal rat (d) cardiomyocytes,
negative controls (b and e), and immunostained desmin in human atrial cells, confirming cardiomyocyte phenotype (c).
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Effect of nesfatin-1 on glucose uptake by
cardiomyocytes
Treatment with nesfatin-1 increased 2-deoxy-D-[3H]
glucose uptake by 12.5  3.9% at 0.1 nM (P  .05, n 
11), by 11.9  4% at 1 nM (P  .05, n  11), and by 26 
5.4% at 100 nM (P  .001, n  11) by HL-1 cardiomy-
ocytes, whereas treatment with 100 nM insulin for 1 hour
increased 2-deoxy-D-[3H]glucose uptake by 44.3  8.8%
(P  .001, n  6) (Figure 4A). Nesfatin-1 also increased
2-deoxy-D-[3H]glucose uptake by primary cultured neo-
natal rat cardiomyocytes significantly by 14.8  3.3% at


















































































































Figure 3. Translocation of glucose transporter GLUT-4 to the cell peripherals in response to nesfatin-1 treatment of neonatal rat cardiomyocytes.
A, Photomicrographs of untreated cells (a–c) and cells treated with 1 M nesfatin-1 (d–f) or 100 nM insulin (g–i), showing anti-GLUT-4 stain (a, d,
and g), TO-PRO-3 nuclear marker (b, e, and h), and the corresponding merged images (c, f, and i). Note the GLUT-4 redistribution from the
cytoplasmic perinuclear area (arrows) to cell peripherals in d and g. Scale bar corresponds to 50 m. B, Ratio of GLUT-4 immunofluorescence in
cell peripherals–cytoplasmic perinuclear regions in experiments showing dependence on the duration (B.1) and intensity (B.2) of exposure to
nesfatin-1 (means of 70 cell peripherals–cytoplasmic perinuclear regions pairs in each of 3 replicate experiments). *, P  .05; ***, P  .001.








































































Figure 4. Uptake of 2-deoxy-D-[3H]glucose by HL-1 (A; n  11) and neonatal rat (B; n  8) cardiomyocytes after 2.5 hours of treatment with
nesfatin-1 (0.1–100 nM) or 1 hour of treatment with 100 nM insulin, relative to untreated controls. *, P  .05; ***, P  .001.
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.001, n  8), whereas treatment with 100 nM insulin for
1 hour increased 2-deoxy-D-[3H]glucose uptake by 35.2 
6.2% (P  .001, n  8) (Figure 4B).
Nesfatin-1 induces AKT, AS160, and ERK1/2
phosphorylation in cardiomyocytes
Because both AKT and ERK1/2 are kinases involved
in the stimulation of GLUT-4 translocation and glucose
uptake in muscle and cardiac cells (35, 36), we inves-
tigated their phosphorylation under nesfatin-1 stimulus
in cultured neonatal rat cardiomyocytes. Nesfatin-1 in-
duced dose- and time-dependent increases in the phos-
phorylation of both AKT and ERK1/2 (Figure 5). In
addition, the AKT substrate of 160 kDa (AS160)
was also phosphorylated after nesfatin-1 treatments
(Figure 5).
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Figure 5. Western blots (WBs) confirmed the activation of AKT, AS160, and ERK1/2 in nesfatin-1-treated neonatal rat cardiomyocytes. A.1,
Dependence of AKT phosphorylation on the nesfatin-1 dose (n  8). A.2, Dependence of AKT (n  8) and AS160 (n  6) phosphorylation on
treatment duration. B, Dependence of ERK1/2 phosphorylation on nesfatin-1 dose (n  7) and on treatment duration (n  6). *, P  .05;
**, P  .01.
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Response of rat cardiac nesfatin-1 levels to diet
The high-fat diet increased nesfatin-1 mRNA/protein
levels in rat atria but not in ventricular tissue (Figure 6A).
Rat atrial NUCB2 mRNA and plasma NUCB2/nesfatin-1
levels were positively correlated with each other and with
body fat as a percentage of body weight (Figure 6A.3).
Gene expression levels of the predominant cardiac fatty
acid transporter CD36 were similar in the hearts of rats fed
with the high-fat and standard diets, and we could not find
any correlation between CD36 and nesfatin-1 cardiac
gene expression levels or between CD36 gene expression
and body weight or percentage of body fat (data not
shown).
Influences on human cardiac nesfatin-1 levels
In the whole group of patients from whom atrial tissue
was obtained, atrial NUCB2 mRNA levels were signifi-
cantly higher in women without coronary injury (CI) than
in those with CI or in men with or without CI (Figure 6B).
No other demographic, anthropometric, biochemical, or
pharmacological parameters were observed to affect





























































































































































































Figure 6. Influence of diet, sex, and coronary injury on cardiac nesfatin-1 levels. A, In rat atrium, the high-fat diet increased NUCB2 gene
expression (A.1; n  8) and nesfatin-1 levels (A.2). A.3, Rat atrial NUCB2 mRNA levels correlated positively with body fat as a percentage of body
weight (n  16) and plasma nesfatin-1 levels (n  10), which correlated positively to body fat (n  10). B, Atrial NUCB2 mRNA levels (median,
[interquartile range]) were higher in women (n  90) than in men (n  178), but lower in women with coronary injury (n  27) than in women
without (n  62). **, P  .01. a.u., arbitrary units.
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Discussion
Adipokines have emerged as the nexus linking obesity,
inflammation, metabolic syndrome, and cardiovascular
disease (37, 38). The ability of nesfatin-1 to cross the
blood-brain barrier suggested the existence of peripheral
sources, and expression of its proprotein NUCB2 was later
observed in a number of extracerebral tissues (see Intro-
duction). Hitherto there have been two reports of NUCB2
expression in cardiac tissue, both in rats (22, 25), but only
Angelone et al (25) detected nesfatin-1 itself, as a band of
approximately 9 kDa in Western blots. In fact, this latter
study and that of Oh-I et al (1) concerning rat cerebrospi-
nal fluid have been the only occasions on which endoge-
nous fully processed mature nesfatin-1 has unequivocally
been observed.
In this work we found that nesfatin-1 is synthesized and
secreted by human and murine cardiomyocytes. Western
blots showed the 9-kDa nesfatin-1 band in lysates of pri-
mary cultures devoid of the other cell types (fibroblasts,
endothelial cells, and erythrocytes) that may be present in
cardiac tissue extracts. Immunostains showed a clear pe-
rinuclear location, very probably in the endoplasmic re-
ticulum or in the Golgi apparatus, both of them typically
located all around the nuclear envelope in cardiomyocytes
(39, 40). Human atrial tissue was also immunoreactive for
prohormone convertase 1/3, the enzyme catalyzing the
cleavage of NUCB2 to yield nesfatin-1.
In culture medium of neonatal rat cardiomyocytes, the
ELISA-measured NUCB2/nesfatin-1 concentration was in
the same range as that detected in the culture medium of
adipose tissue explants (6).
Recent reports suggested that nesfatin-1 acts as a mul-
tifunctional metabolic hormone. In particular, there is
considerable evidence of its being a glucose-dependent co-
adjuvant of insulin, because it has an antihyperglycemic
effect (18) and influences the excitability of glucosensing
neurons in rat hypothalamus (20), being able to stimulate
glucose-induced insulin release and insulin sensitivity in
rats and in mouse islet -cells (13, 19, 41) and secretion of
glucagon from mouse pancreatic islets (17). Moreover, the
release of NUCB2/nesfatin-1 from rat pancreatic islets is
stimulated by glucose (13), and plasma glucose and
NUCB2/nesfatin-1 levels are negatively correlated in rats
and in patients with type 2 diabetes (5, 8, 16). However,
ours is the first study of its direct effect on GLUT-4 (the
main glucose transporter in the heart) translocation. We
found that in cultured cardiomyocytes nesfatin-1 alters the
distribution of GLUT-4, favoring translocation from the
cytoplasmic perinuclear regions to cell peripherals to an
extent similar to that induced by insulin, and thus appears
to be directly involved in the regulation of cardiomyocyte
glucose metabolism. Moreover, our results show that nes-
fatin-1 induces an increase in glucose uptake by HL-1
mouse cardiac cells and neonatal rat cardiomyocytes in
culture. A similar direct effect has been observed previ-
ously only in adipocytes from nesfatin-1–treated rats, in
which both basal and insulin-induced glucose uptake were
significantly increased (13). Note that the concentrations
of nesfatin-1 in our experiments, as in several other recent
studies of its cellular effects (17, 23, 42, 43), were orders
of magnitude higher than the nanomolar concentrations
found in human and murine plasma (6, 7, 16), suggesting
that in vivo these effects might require a local nesfatin-1
source.
Nesfatin-1 induced dose- and time-dependent increases
in the phosphorylation of AKT and ERK1/2, which are
both involved in promoting GLUT-4 translocation and
glucose uptake in muscle and cardiac cells (35, 36). Our
findings parallel observations that central nesfatin-1 ad-
ministration in rats induces AKT activation in hypotha-
lamic nuclei that mediate glucose homeostasis (19) and
that ERK1/2 is activated by nesfatin-1 treatment in per-
fused rat hearts (25) (although without AKT activation).
In cardiomyocytes, nesfatin-1 promotes the phosphor-
ylation of the AKT substrate AS160, the most distal insu-
lin-signaling protein that has been linked to GLUT-4
translocation (44). Of note, ours are the first results show-
ing that nesfatin-1 can induce the phosphorylation of
AS160, and this could indeed help to clarify the physio-
logical/pathophysiological roles of nesfatin-1 in glucose
and energy metabolism suggested previously by others
(45). Under basal conditions, the Rab GTPase-activating
protein domain of AS160 stimulates hydrolysis of Rab-
associated GTP and the formation of the inactive GDP-
bound Rab, which restrains GLUT-4 exocytosis; however,
insulin-stimulated phosphorylation of AS160 by AKT re-
lieves this restraint by leading to an increase in the GTP-
bound Rab which, in turn, favors greater GLUT-4 exo-
cytosis to cell surface membranes (44, 46). AS160 is
considered to be a point of convergence for coordinating
physiological regulation of GLUT-4 membrane recruit-
ment in cardiomyocytes (47).
In rodents, synthesis of nesfatin-1 (or at least NUCB2)
appears to respond to diet or nutritional status both cen-
trally in the hypothalamic paraventricular nucleus (1, 48)
and in peripheral tissues such as the stomach (49), adipose
tissue (6), and heart (this work), where it may help control
energy expenditure and may respond to developmental
and hormonal signals as well as to metabolic status. The
finding that cardiac and plasma NUCB2/nesfatin-1 levels
are positively correlated and that both correlate with body
fat is in keeping with a report that plasma NUCB2 con-
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centrations are higher in mice with diet-induced obesity
than in nonobese mice (6).
Obesity imposes a metabolic stress to the heart, which
may ultimately lead to cardiac metabolic inflexibility and
lipotoxicity, because the fatty acid transporter CD36 is
responsible for the chronically increasing uptake of fatty
acids by the cardiac muscle under those circumstances
(36). In this work, the high-fat diet did not induce changes
in cardiac CD36 gene expression, and there was no cor-
relation between cardiac CD36 and nesfatin-1 levels;
however, we cannot exclude the possibility that nesfatin-1
could affect the surface presence of CD36 and its trans-
location from intracellular storage compartments, and fu-
ture experiments should clarify a possible involvement of
this peptide in the complex interplay between signaling
pathways and trafficking components known to be in-
volved in the regulation of GLUT-4 and CD36 transloca-
tion (36).
Only 2 previous studies have investigated NUCB2/nes-
fatin-1 regulation in human cells or tissues. Yamada et al
(50) found that troglitazone stabilizes NUCB2 mRNA
through ERK1/2 activation in a human medulloblastoma
cell line, and Riva et al (17) found that NUCB2 deficiency
in the pancreatic islets of type 2 diabetes patients can be
remedied by culture in glucolipotoxic conditions. In the
present study, atrial NUCB2 mRNA levels were signifi-
cantly higher in women without coronary lesions than in
other patients, suggesting a sex-dependent relationship
between cardiac nesfatin-1 levels and cardiovascular
disease.
In conclusion, nesfatin-1 is synthesized and helps to
regulate glucose metabolism in the hearts of humans and
experimental animals, where its levels vary with diet and
ischemic cardiomyopathy.
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